PuSH - Publication Server of Helmholtz Zentrum München: Large B-cell lymphoma imprints a dysfunctional immune phenotype that persists years after treatment.

Information

Clues to quality of journals

Open Access Policy of Helmholtz Association 2016

CC Licencences

Publication Metrics

Navigation

Home

Deutsch

EVA: Electronic Publishing

New EVA Application

Research

Advanced Search

Browse by ...

... HMGU-Authors/Consortia

... Organizational Structure

... Journal

... Publication Type

... Research Data

... Arbeitsgruppen

... Publication Year

Publication overview

Statistics

Statistics (last 5 years)

OA Publications

Publish

Submit Publication

Import publication from...

...EVA

Report missing publication

Highlights

Support & Contact

Contact persons

Help

Data protection

Helmholtz Open Science

JANE Journal Estimator

SHERPA/RoMEO

DOAJ

Export:

Text

Endnote (RIS) BIB

BibTeX

Pelzl, R.* ; Benintende, G.* ; Gsottberger, F.* ; Scholz, J.K.* ; Ruebner, M.* ; Yao, H.* ; Wendland, K.* ; Rejeski, K.* ; Altmann, H.* ; Petkovic, S.* ; Mellenthin, L.* ; Kübel, S.* ; Schmiedeberg, M.* ; Klein, P.* ; Petrera, A. ; Baur, R.* ; Eckstein, S.* ; Hoepffner-Grundy, S.* ; Röllig, C.* ; Subklewe, M.* ; Huebner, H.* ; Schett, G.* ; Mackensen, A.* ; Laurenti, L.* ; Graw, F.* ; Völkl, S.* ; Nganou-Makamdop, K.* ; Müller, F.*

Large B-cell lymphoma imprints a dysfunctional immune phenotype that persists years after treatment.

Blood 146, 1300-1313 (2025)

Publ. Version/Full Text

Research data

DOI

PMC

	Open Access Hybrid

Abstract
Metrics
Extra information

Immunotherapy has become standard of care in the treatment of diffuse large B-cell lymphoma (DLBCL). Changes in immunophenotypes observed at first diagnosis predict therapy outcome but little is known about the resolution of these alterations in remission. Comprehensive characterization of immune changes from fresh, peripheral whole blood revealed a functionally relevant increase of myeloid-derived suppressor cells, reduced naïve T-cells, and an increase of activated and terminally differentiated T-cells before treatment which aggravated after therapy. Suggesting causal relation, injection of lymphoma in mice induced similar changes in the murine T cells. Distinct immune imprints were found in breast cancer and AML survivors. Identified alterations persisted beyond five years of ongoing complete remission and in DLBCL correlated with increased pro-inflammatory markers such as IL-6, B2M, or sCD14. The chronic inflammation was associated with functionally blunted T-cell immunity against SARS-CoV-2-specific peptides and reduced responses correlated with reduced Tn-cells. Persisting inflammation was confirmed by deep sequencing and by cytokine profiles, together pointing towards a compensatory activation of innate immunity. The persisting, lymphoma-induced immune alterations in remission may explain long-term complications, have implications for vaccine strategies, and are likely relevant for immunotherapies.

Impact Factor

Scopus SNIP

Web of Science
Times Cited

Altmetric

23.100

0.000